Phase 2 Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

Trial Profile

Phase 2 Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2014

At a glance

  • Drugs OMS 824 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Omeros Corporation
  • Most Recent Events

    • 14 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2014 Early findings will be presented at the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) according to an Omeros Corporation media release.
    • 19 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Apr 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top